Schott and Credence MedSystems have formed a strategic collaboration to make syringe injections safer through integration of Schott’s pre-fillable syriQ glass and the Credence Companion technology.
As reported in an Oct. 5, 2020 press release, the companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for drug delivery via prefilled syringes. The combination of Schott’s and Credence’s offerings targets a pre-validated and pre-assembled portfolio of passive integrated needle systems with various available syringe sizes made of both glass and high-quality Cyclic Olefin Copolymer materials.
“Integrating our established Companion technology with a broad variety of existing syringe barrels from Schott is an important milestone in offering innovation without change to the pharmaceutical industry,” said John Merhige, Credence’s chief commercial officer, in the press release. “This allows pharma the confidence to work with already validated systems but the freedom to choose the perfect fit from a wide portfolio.”
Fabian Stöcker, vice president of Global Strategy and Innovation at Schott Pharmaceutical Systems added, in the press release, “Having over 20 years of experience in the field of syringes, we are happy that, with this partnership and product offering, we can even go a step further to create a new, synergistic, and trusted offering for glass and polymer syringe systems that is responsive to the growing needs of the industry. To our knowledge, we will provide the first integrated needle safety system on the market with a polymer pre-fillable syringe by integrating the Credence Companion technology into our Schott TOPPAC syringes.”
